Sector News

AstraZeneca CEO: We want a ‘strong, science-led FDA’

February 2, 2017
Life sciences

The chief of AstraZeneca Pascal Soriot said during the Big Pharma’s financials this morning that he wants a “science-led FDA” as President Donald Trump’s administration looks to slash regulations, and potentially staff, from across the agency.

In the Q4 update call to journalists and analysts, Soriot said: “We actually believe in a strong, science-led FDA. We are a science-led organization that thrives to hit high scientific standards and so we would expect the FDA to be well staffed and focused also on those standards.”

But he said that there are always opportunities to “do things better” and so “we continue to engage with the FDA to do what that have done very successfully in oncology over the past few years, which is finding new pathways to accelerate approvals of new drugs or indications.

“If you look back over the past few years, quite a number of breakthroughs in cancer in oncology have been brought to patients in the U.S., and the oncology department [from the FDA] has been trailblazing from the point of view.”

He cautioned that there is a limit to “how fast we can go in doing those things well.”

This comes as Trump sat down with a number of Big Pharma chiefs earlier this week and said he was seeking to cut down on regulations at the FDA, and was also likely to, as part of a broader hiring freeze across the country for federal employees, reduce headcount at the agency in the coming years through attrition.

Trump said at the meeting: “We’re going to get rid of a tremendous number of regulations. We’re going to be cutting regulations like nobody has ever seen before. And we’re going to have tremendous protections for the people, perhaps even more protections for the people. We’re going to streamline the FDA.

“We have a fantastic person [to lead the Agency] that I think I will be naming very soon. We’re going to streamline the FDA. You’re going to get your products either approved or not approved but it’s going to be a quick process. It’s not going to take 15 years.”

This was largely backed by biopharma groups BIO and PhRMA, but was criticized by U.S. lawmakers.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.